US Food and Drug Administration has decided to recommend a discussion of naloxone when prescribing an opioid, stopping short of a potentially costly co-prescribing requirement that had been narrowly recommended by an advisory committee.
The agency will require opioid and opioid use disorder product labels to include language recommending “that as a routine part...




